Peptides DB
Research-centric peptide and protocol reference hub

PT-141 (Bremelanotide) record · updated 18h ago

Neuro & moodHealing & recoveryGrade A · human clinicalResearch use only
All 22 studiesJump to the evidenceCompare
What is PT-141 (Bremelanotide) used for?

PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.

How it works: Melanocortin receptor agonist

Primarily researched for · Neuro & moodRoute · Subcutaneous injection

Development stage

where PT-141 (Bremelanotide) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 10 registered trials. It describes the research record, not a recommendation.

Identity
NamePT-141 (Bremelanotide)
Chain length—
Molecular weight1,025.2 Da
FormulaC50H68N14O10
Structure typeNot established
ClassNeuro
Research levelFDA Approved
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 9941379. No verified residue count for this compound.

Pharmacology
MechanismMelanocortin receptor agonist
RouteSubcutaneous injection
Half-life~2.7 hours
Time to peak1 hour
DurationUp to 24 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 6, 2026. How this works →
Research stats
Total studies22
Human / animal / cellular6 / 3 / 1
Highest trial phasePreclinical
Years covered2010–2026
Latest study1mo ago
Publication history
20102026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

22 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Multifunctional material platforms for neural interfaces: active orchestration of dynamic foreign body response across implantation lifetimes.
TakeawayBio-inspired materials may enhance the longevity of brain-computer interfaces by modulating the foreign body response, but further empirical validation is needed.
review2026Full text read0.80
An interpretable machine learning model for predicting febrile seizures following enterovirus infection in children.
FindingXGBoost model training set AUC was 0.972 (95% CI: 0.958-0.987).
Human2026Full text read0.80
Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.
TakeawaySensing-integrated organoid-on-a-chip platforms may revolutionize real-time monitoring in biomedical research, but empirical validation is necessary to confirm their clinical utility.
review2026Full text read0.80
Smart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.
TakeawaySmart-responsive electrospun scaffolds represent a promising avenue for neural repair, but further research is needed to translate these findings into clinical practice.
review2026Full text read0.80
HMB supplementation combined with high-intensity functional exercise supports aerobic capacity but not strength in trained and untrained males: a randomized controlled trial.
FindingVO2MAX increased with HMB in TR, p=0.024.
Human2026Full text read0.90
Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.
TakeawayMicroneedle platforms are evolving from passive delivery systems to active therapeutic interfaces, offering potential in systemic disease management but facing significant translational challenges.
review2026Full text read0.80
Analysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.
Finding34,498 RA-related adverse events (0.03%) among 11,532,185 reports.
Human2026Full text read0.80
Lifespan brain structural variation reveals shared organization across mental health conditions
FindingNot reported in abstract.
Human2024Full text read0.80
Sexual arousal: Sex matters.
TakeawayNot reported in abstract.
—2017Title only0.20
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
FindingTerminal elimination half-life of 24 h (3 mg/kg), 34 h (6 mg/kg), and 53 h (12 mg/kg).
Human2026Full text read0.90
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.
Finding150 mg/kg PCZ in mice, n=126; 350 mg/kg PCZ in monkeys, n=10.
Animal2026Full text read0.80
Risk stratification for in-hospital mortality in sepsis-associated acute kidney injury patients receiving continuous renal replacement therapy: an interpretable, externally validated machine learning study.
FindingAUC of 0.890 in training cohort, n=1217.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching PT-141 (Bremelanotide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much PT-141 (Bremelanotide) is discussed should be drawn from it.

Articles mentioning PT-141 (Bremelanotide)